The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease
Abstract
Introduction: Alzheimer’s disease (AD) is the most common cause of major neurocognitive disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden projected to increase dramatically in the coming years, it is imperative to review the current available treatment regimens for their safety and utility. The cholinesterase inhibitors (ChEIs) have continued to play a pivotal role in managing the symptoms and possibly slowing the rate of progression of AD since 1993. Owing to their being a mainstay in the treatment of AD, the safety and efficacy of prescribing these drugs needs to be reviewed often, especially with the approval of new formulations and doses.Areas covered: The three ChEIs currently approved by the FDA are donepezil, rivastigmine and galantamine. This article will review the safety and tolerability of these ChEIs and analyze the potential disease modifying properties of these drugs. The authors have reviewed all recent literature including review articles, meta-analyzes, clinical trials and more.Expert opinion: These ChEIs differ subtly in their mechanisms of action, in their tolerability and safety and FDA-approved indications. All are considered first-line, symptomatic treatments of the various phases of AD and may even have potentially disease-modifying effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627 · cited 1×
“The cholinergic hypothesis suggests that reduced brain acetylcholine (ACh) levels due to the atrophy of cholinergic neurons, primarily in the nucleus basalis of Meynert are the cause of cognitive decline in AD [8].”
Background2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384
Self-citationClinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365 · cited 1×
“Rivastigmine also remains unmetabolized by the CYP-450 system, reducing the potential for drug-drug interactions [47,48].”
BackgroundA review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease
Nordberg, A., Ballard, C., Bullock, R., Darreh-Shori, T., & Somogyi, M. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01412 · Cited by 323 · cited 3×
“Acetylcholinesterase (AChE) and Butyrylcholinesterase (BChE) are 2 main enzymes that hydrolyze Ach in the brain [7].”
BackgroundCurrent and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309 · cited 2×
“5 mg and titrating to 5 mg over the course of 6 weeks, can be helpful in patients who are sensitive to cholinergic side effects [20].”
BackgroundCholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials
Qizilbash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L., Farlow, M., & for the Dementia Trialists' Collaboration (1998) · JAMA · doi:10.1001/jama.280.20.1777 · Cited by 161
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial
Campbell, N. L., Perkins, A. J., Gao, S., Skaar, T. C., Li, L., Hendrie, H. C., Fowler, N., Callahan, C. M., & Boustani, M. A. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14827 · Cited by 58
Cited by
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Guo, J., Wang, Z., Liu, R., Huang, Y., Zhang, N., & Zhang, R. (2020) · Brain and Behavior · doi:10.1002/brb3.1831 · Cited by 165
Ji, Y.-J., Kim, S., Kim, J.-J., Jang, G. Y., Moon, M., & Kim, H. D. (2021) · Antioxidants · doi:10.3390/antiox10121968 · Cited by 20
Wu, Y.-W., HuangFu, W.-C., Lin, T. E., Peng, C.-H., Tu, H.-J., Sung, T.-Y., Sung, T.-Y., Yen, S.-C., Pan, S.-L., & Hsu, K.-C. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.129074 · Cited by 15
Metadata
- Authors
- Haake, A., Nguyen, K., Friedman, L., Chakkamparambil, B., & Grossberg, G. T.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2020-01-28
- Volume
- 19
- Issue
- 2
- Pages
- 147-157
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W3002574516
- Cited by
- 181
- References
- 10
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. https://app.cochat.ai/papers/10.1080/14740338.2020.1721456
- The paper
- Haake, A., Nguyen, K., Friedman, L., Chakkamparambil, B., & Grossberg, G. T. (2020). An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2020.1721456
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.